“The DRC authorities, in deciding to deploy the second experimental vaccine to extend protection against this deadly virus, have once again shown leadership and their determination to end this outbreak as soon as possible.”

Details: The DRC will introduce the second experimental vaccine made by Johnson & Johnson starting in mid-October, the WHO says. It will complement the current vaccine made by Merck, which is also experimental but has preliminary results showing high effectiveness.

• J&J's vaccine was initially considered to be harder to distribute logistically, since it requires 2 doses given 56 days apart — tough to do especially in areas with a highly mobile population and many refugees.
• However, the DRC is planning to use this experimental vaccine in communities outside of the Ebola hot spots in an effort to prevent the outbreak from reaching new regions.

Meanwhile, the WHO issued a statement Saturday warning that there may be at least one undiagnosed case in Tanzania, adding that it is trying to discern the situation there but were finding Tanzanian officials unresponsive to its requests for more information.

Go deeper:

• The Ebola virus is winning in Eastern Democratic Republic of the Congo (CSIS commentary)
• One year on — No end in sight for deadly Ebola outbreak (Axios)
• Ebola vaccine's effectiveness is imperiled by DRC's unrest (Axios)

• Ilunga was first arrested less than a month ago for reported misdemeanor offenses.

The big picture: The DRC Ministry of Health reports a total of 3,002 confirmed Ebola cases as of Friday, with 942 people cured. WHO's latest report said that 56% of people afflicted with confirmed and probable Ebola cases were women.

Go deeper: One year on and no end in sight for deadly Ebola outbreak